Biotech Specialty Pharma

Affymax

4001 Miranda Avenue
Palo Alto, CA 94304 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Peptide-based drugs for kidney diseases and cancer.

Management Arlene M. Morris, President and Chief Executive Officer; Paul B. Cleveland, Chief Financial Officer and Executive Vice President; Anne-Marie Duliege, M.D., M.S., Chief Medical Officer; Jeffrey H. Knapp, Chief Commercial Officer; Kay Slocum, Senior Vice President, Human Resources

Click here for Financial Data
Keywords: hematide, hemoglobin, hronic renal failure, heart failure, inflammatory

Comment


Updated: Nov. 11, 2014


Description

Affymax is developing a rich pipeline of synthetic peptide-based drugs against clinically validated targets for the treatment of kidney diseases and cancer.......view more

Products / Services

The company's lead productHematide is a synthetic peptide-based erythropoiesis-stimulating agent (ESA) in clinical development for anemia due to chronic kidney disease (CKD) and cancer. Hematide is in......view more

Technology / Differentiation

Affymax has amassed significant expertise in peptide drug discovery and development, including capabilities in creating long acting versions of drugs using PEGylation technology. While the companys c...view more

RELATED COMPANIES



    0000-00-00-2068